ImmunityBio, Inc.
IBRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $32,061 | $26,425 | $16,517 | $7,552 |
| % Growth | 21.3% | 60% | 118.7% | – |
| Cost of Goods Sold | $4,128 | $136 | $58 | $0 |
| Gross Profit | $27,933 | $26,289 | $16,459 | $7,552 |
| % Margin | 87.1% | 99.5% | 99.6% | 100% |
| R&D Expenses | $50,732 | $55,236 | $48,234 | $35,221 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $32,831 | $42,338 | $32,654 | $41,731 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $83,563 | $97,574 | $80,888 | $76,952 |
| Operating Income | -$55,630 | -$71,285 | -$64,429 | -$69,400 |
| % Margin | -173.5% | -269.8% | -390.1% | -919% |
| Other Income/Exp. Net | -$11,679 | -$21,020 | -$65,471 | $10,221 |
| Pre-Tax Income | -$67,309 | -$92,305 | -$129,900 | -$59,179 |
| Tax Expense | -$35 | $269 | -$234 | $0 |
| Net Income | -$67,253 | -$92,555 | -$129,646 | -$59,162 |
| % Margin | -209.8% | -350.3% | -784.9% | -783.4% |
| EPS | -0.071 | -0.1 | -0.15 | -0.08 |
| % Growth | 29% | 33.3% | -87.5% | – |
| EPS Diluted | -0.071 | -0.1 | -0.15 | -0.09 |
| Weighted Avg Shares Out | 946,601 | 888,216 | 853,162 | 733,204 |
| Weighted Avg Shares Out Dil | 946,601 | 888,216 | 853,162 | 734,542 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,096 | $818 | $520 | $769 |
| Interest Expense | $27,584 | $28,884 | $28,865 | $14,905 |
| Depreciation & Amortization | $3,951 | $3,880 | $3,829 | $4,154 |
| EBITDA | -$35,774 | -$59,541 | -$97,206 | -$40,120 |
| % Margin | -111.6% | -225.3% | -588.5% | -531.3% |